Semaglutide (Wegovy, Ozempic) aims at one receptor (GLP-1), while tirzepatide (Zepbound, Mounjaro) homes in on two (GLP-1 and GIP)
Expected weight change: 1 to 3% of body weight over four weeks (roughly 2 to 6 pounds for a 200-pound person)
They show up in clinical trial design, in tolerability profiles, in the types of metabolic benefits each compound delivers, and in the practical timelines for when researchers might actually be able to access them
It is the foundation of several breakthrough medications that are revolutionizing the treatment of obesity and type 2 diabetes
Research Overview Retatrutide is a next-generation multi-agonist peptide that engages GIP, GLP-1 and glucagon receptors simultaneously
Gastrointestinal issues can also indirectly cause stress